ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who had never been treated with a complement inhibitor (treatment-naïve).

Study Overview

• Status: Completed
• Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Intervention / Treatment: Biological: Ravulizumab; Biological: Eculizumab

Detailed Description

The study consisted of a 4-week screening period and a 26-week randomized treatment period (Primary Evaluation Period). After completion of the 26-week Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive ravulizumab for up to 5 years.

This study is ongoing. The data presented is for the Primary Evaluation Period. The results for the Extension Period will be reported after study completion.

• Study Type: Interventional
• Enrollment (Actual): 270
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, C1015ABO
    • Clinical Trial Site
  • Buenos Aires, Argentina, C1425AUM
    • Clinical Trial Site
  • Córdoba, Argentina
    • Clinical Trial Site
• Australia
  • Perth, Australia
    • Clinical Trial Site
• Austria
  • Linz, Austria
    • Clinical Trial Site
  • Vienna, Austria
    • Clinical Trial Site
• Belgium
  • Hasselt, Belgium
    • Clinical Trial Site
  • Leuven, Belgium
    • Clinical Trial Site
• Brazil
  • Belém, Brazil
    • Clinical Trial Site
  • Rio de Janeiro, Brazil
    • Clinical Trial Site
  • Salvador, Brazil
    • Clinical Trial Site
  • São Paulo, Brazil, 05403-000
    • Clinical Trial Site
  • São Paulo, Brazil, 08270-070
    • Clinical Trial Site
• Canada
  • Edmonton, Canada
    • Clinical Trial Site
  • Toronto, Canada
    • Clinical Trial Site
• Czechia
  • Plzen, Czechia
    • Clinical Trial Site
  • Praha, Czechia
    • Clinical Trial Site
• Estonia
  • Tallinn, Estonia
    • Clinical Trial Site
• France
  • Limoges, France
    • Clinical Trial Site
  • Montpellier, France
    • Clinical Trial Site
  • Paris, France
    • Clinical Trial Site
  • Pierre-Bénite, France
    • Clinical Trial Site
  • Rennes, France
    • Clinical Trial Site
  • Vienne
    • Poitiers, Vienne, France
      • Clinical Trial Site
• Germany
  • Essen, Germany
    • Clinical Trial Site
  • Ulm, Germany
    • Clinical Trial Site
• Italy
  • Ascoli Piceno, Italy
    • Clinical Trial Site
  • Firenze, Italy
    • Clinical Trial Site
  • Milano, Italy
    • Clinical Trial Site
  • Napoli, Italy
    • Clinical Trial Site
  • Vicenza, Italy
    • Clinical Trial Site
• Japan
  • Bunkyō-Ku, Japan, 113-8431
    • Clinical Trial Site
  • Bunkyō-Ku, Japan
    • Clinical Trial Site
  • Fukuoka, Japan
    • Clinical Trial Site
  • Fukushima, Japan
    • Clinical Trial Site
  • Hamamatsu-shi, Japan
    • Clinical Trial Site
  • Kanazawa-shi, Japan
    • Clinical Trial Site
  • Koshigaya-shi, Japan
    • Clinical Trial Site
  • Kumamoto, Japan
    • Clinical Trial Site
  • Nishinomiya-shi, Japan
    • Clinical Trial Site
  • Ogaki-shi, Japan
    • Clinical Trial Site
  • Okayama-city, Japan
    • Clinical Trial Site
  • Okayama-shi, Japan
    • Clinical Trial Site
  • Osakasayama-shi, Japan
    • Clinical Trial Site
  • Sapporo, Japan
    • Clinical Trial Site
  • Shimotsuke-shi, Japan
    • Clinical Trial Site
  • Shinagawa-Ku, Japan
    • Clinical Trial Site
  • Shinjuku-Ku, Japan, 160-0023
    • Clinical Trial Site
  • Shinjuku-Ku, Japan, 160-8582
    • Clinical Trial Site
  • Suita-shi, Japan
    • Clinical Trial Site
  • Tokorozawa-shi, Japan
    • Clinical Trial Site
  • Toyoake-shi, Japan
    • Clinical Trial Site
  • Tsukuba, Japan
    • Clinical Trial Site
  • Wakayama-shi, Japan
    • Clinical Trial Site
  • Yokohama-City, Japan, 227-8501
    • Clinical Trial Site
  • Yokohama-City, Japan, 236-0004
    • Clinical Trial Site
• Korea, Republic of
  • Anyang-si, Korea, Republic of
    • Clinical Trial Site
  • Busan, Korea, Republic of
    • Clinical Trial Site
  • Daegu, Korea, Republic of
    • Clinical Trial Site
  • Incheon, Korea, Republic of
    • Clinical Trial Site
  • Jeonju, Korea, Republic of
    • Clinical Trial Site
  • Jinju-si, Korea, Republic of
    • Clinical Trial Site
  • Seoul, Korea, Republic of, 02841
    • Clinical Trial Site
  • Seoul, Korea, Republic of, 03080
    • Clinical Trial Site
  • Seoul, Korea, Republic of, 03722
    • Clinical Trial Site
  • Seoul, Korea, Republic of, 04401
    • Clinical Trial Site
  • Seoul, Korea, Republic of, 05505
    • Clinical Trial Site
  • Seoul, Korea, Republic of, 06351
    • Clinical Trial Site
  • Seoul, Korea, Republic of, 06591
    • Clinical Trial Site
  • Seoul, Korea, Republic of, 07985
    • Clinical Trial Site
  • Seoul, Korea, Republic of, 08308
    • Clinical Trial Site
  • Suwon-si, Korea, Republic of, 16247
    • Clinical Trial Site
  • Suwon-si, Korea, Republic of, 16499
    • Clinical Trial Site
  • Ulsan, Korea, Republic of
    • Clinical Trial Site
• Malaysia
  • Ampang, Malaysia
    • Clinical Trial Site
  • Johor Bahru, Malaysia
    • Clinical Trial Site
  • Kota Bahru, Malaysia, 16150
    • Clinical Trial Site
  • Kota Bharu, Malaysia, 15586
    • Clinical Trial Site
  • Kota Kinabalu, Malaysia
    • Clinical Trial Site
  • Kubang Kerian, Malaysia
    • Clinical Trial Site
  • Kuching, Malaysia
    • Clinical Trial Site
  • Pulau Pinang, Malaysia
    • Clinical Trial Site
  • Kelantan
    • Kota Bharu, Kelantan, Malaysia
      • Clinical Trial Site
  • Sarawak
    • Miri, Sarawak, Malaysia
      • Clinical Trial Site
    • Sibu, Sarawak, Malaysia
      • Clinical Trial Site
• Mexico
  • Monterrey, Mexico
    • Clinical Trial Site
• Poland
  • Gdańsk, Poland
    • Clinical Trial Site
  • Warsaw, Poland
    • Clinical Trial Site
• Russian Federation
  • Arkhangel'sk, Russian Federation
    • Clinical Trial Site
  • Barnaul, Russian Federation
    • Clinical Trial Site
  • Bryansk, Russian Federation
    • Clinical Trial Site
  • Irkutsk, Russian Federation
    • Clinical Trial Site
  • Kaluga, Russian Federation
    • Clinical Trial Site
  • Kirov, Russian Federation
    • Clinical Trial Site
  • Krasnodar, Russian Federation, 350007
    • Clinical Trial Site
  • Krasnoyarsk, Russian Federation, 660003
    • Clinical Trial Site
  • Krasnoyarsk, Russian Federation, 660022
    • Clinical Trial Site
  • Moscow, Russian Federation, 125167
    • Clinical Trial Site
  • Moscow, Russian Federation, 125284
    • Clinical Trial Site
  • Murmansk, Russian Federation
    • Clinical Trial Site
  • Nizhny Novgorod, Russian Federation
    • Clinical Trial Site
  • Novosibirsk, Russian Federation
    • Clinical Trial Site
  • Petrozavodsk, Russian Federation
    • Clinical Trial Site
  • Rostov-na-Donu, Russian Federation
    • Clinical Trial Site
  • Saint Petersburg, Russian Federation
    • Clinical Trial Site
  • Saratov, Russian Federation
    • Clinical Trial Site
  • Ufa, Russian Federation
    • Clinical Trial Site
• Singapore
  • Singapore, Singapore
    • Clinical Trial Site
• Spain
  • Barcelona, Spain
    • Clinical Trial Site
  • Madrid, Spain
    • Clinical Trial Site
  • Majadahonda, Spain
    • Clinical Trial Site
• Sweden
  • Uppsala, Sweden
    • Clinical Trial Site
• Taiwan
  • Chang-hua, Taiwan
    • Clinical Trial Site
  • Hualien City, Taiwan
    • Clinical Trial Site
  • Kaohsiung, Taiwan
    • Clinical Trial Site
  • Taichung, Taiwan
    • Clinical Trial Site
  • Tainan, Taiwan
    • Clinical Trial Site
  • Taipei, Taiwan
    • Clinical Trial Site
• Thailand
  • Bangkok, Thailand
    • Clinical Trial Site
  • Hat Yai, Thailand
    • Clinical Trial Site
  • Pathum Wan, Thailand
    • Clinical Trial Site
• Turkey
  • Eskişehir, Turkey
    • Clinical Trial Site
• United Kingdom
  • Leeds, United Kingdom
    • Clinical Trial Site
  • London, United Kingdom
    • Clinical Trial Site
• United States
  • California
    • Los Angeles, California, United States, 90048
      • Clinical Trial Site
    • Los Angeles, California, United States, 90033
      • Clinical Trial Site
  • Texas
    • Fort Worth, Texas, United States, 76104
      • Clinical Trial Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Criteria For Patient Cohort Originally Enrolled in ALXN1210-PNH-301 Study:

Inclusion Criteria:

1. Male or female ≥18 years of age.
2. PNH diagnosis confirmed by documented by high-sensitivity flow cytometry.
3. Presence of 1 or more of the following PNH-related signs or symptoms within 3 months of screening: fatigue, hemoglobinuria, abdominal pain, shortness of breath (dyspnea), anemia (hemoglobin <10 gram/deciliter), history of a major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction; or history of packed red blood cells (pRBC) transfusion due to PNH.
4. Lactate dehydrogenase (LDH) level ≥1.5 times the upper limit of normal at screening.
5. Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment.
6. Female participants of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ravulizumab.
7. Willing and able to give written informed consent and comply with study visit schedule.

Exclusion Criteria:

1. Treatment with a complement inhibitor at any time.
2. History of bone marrow transplantation.
3. Body weight <40 kg.
4. Females who are pregnant, breastfeeding, or who have a positive pregnancy test at screening or Day 1.
5. Participation in another interventional clinical study or use of any experimental therapy within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives of that investigational product, whichever is greater.
6. History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic disease that, in the opinion of the investigator or sponsor, would preclude participation.
7. Unstable medical conditions (for example, myocardial ischemia, active gastrointestinal bleed, severe congestive heart failure, anticipated need for major surgery within 6 months of randomization, coexisting chronic anemia unrelated to PNH).

Eligibility Criteria For Roll-over Cohort:

1. All participants regardless of age, who are currently receiving ALXN1210 IV in an ongoing ALXN1210 study in patients with PNH
2. Participants must be willing and able to give written informed consent and to comply with all Extension study visits and procedures, including the use of any data collection device(s) to directly record patient data
3. Females of childbearing potential and male patients with female partners of childbearing potential must use highly effective contraception continuing until at least 8 months after the last dose of ravulizumab.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ravulizumab; Participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligram (mg) on Day 1. Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Day 15 and every 8 weeks thereafter for 26 weeks. After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years.	Biological: Ravulizumab; All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to <60 kilogram (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to <100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.; Other Names: ALXN1210; ULTOMIRIS
Active Comparator: Eculizumab; Participants received 600 mg of eculizumab on Days 1, 8, 15, and 22, followed by 900 mg of eculizumab on Day 29 and every 2 weeks thereafter for 26 weeks. After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years.	Biological: Ravulizumab; All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to <60 kilogram (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to <100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.; Other Names: ALXN1210; ULTOMIRIS; Biological: Eculizumab; All treatments were given as IV infusions. Participants were administered induction doses of 600 mg followed by maintenance doses of 900 mg.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion Of Participants With Normalization Of Lactate Dehydrogenase (LDH) Levels	LDH is an indicator of intravascular hemolysis that occurs in patients with paroxysmal nocturnal hemoglobinuria (PNH). A decrease in LDH from above the upper limit of normal (ULN) to below the ULN indicates reduction (improvement) in hemolysis. Normalization of LDH levels (LDH-N) was LDH levels less than or equal to 1 x ULN, from Day 29 through Day 183. The ULN for LDH is 246 U/L.	Day 29 through Day 183
Percentage Of Participants Who Achieved Transfusion Avoidance (TA)	Transfusion avoidance was defined as the percentage of participants who remained transfusion free and did not require a transfusion per protocol-specified guidelines through Day 183.	Baseline through Day 183

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage Of Participants With Breakthrough Hemolysis (BTH)	Breakthrough hemolysis was defined as at least 1 new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath [dyspnea], anemia [hemoglobin <10 gram/deciliter (g/dL)], major adverse vascular event [MAVE, including thrombosis], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 × ULN, after prior LDH reduction to <1.5 × ULN on therapy.	Baseline through Day 183
Percent Change From Baseline In Lactate Dehydrogenase (LDH) Levels	Baseline is defined as the average of all available assessments of LDH levels prior to first study drug dose. Estimates are based on Mixed Model for Repeated Measures (MMRM) that includes treatment group, history of transfusion (as a categorical variable based on the stratification factor levels) and baseline LDH level (as a continuous variable), study visit and study visit by treatment group interaction. An unstructured covariance structure was used.	Baseline, Day 183
Change From Baseline In Quality Of Life As Assessed By The Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue	FACIT-Fatigue score ranges from 0 to 52, with a higher score indicating less fatigue. Baseline is defined as the last non-missing value prior to first dose of study drug. Estimates are based on MMRM that includes treatment group, the observed stratification randomization indicators (history of transfusion and LDH) and baseline FACIT-Fatigue level, study visit, and study visit by treatment group interaction. An unstructured covariance structure was used.	Baseline, Day 183
Percentage Of Participants With Stabilized Hemoglobin Levels	Stabilized hemoglobin was defined as avoidance of a ≥2 g/dL decrease in hemoglobin level from baseline in the absence of transfusion through Day 183.	Baseline through Day 183

Collaborators and Investigators

• Sponsor: Alexion

Publications and helpful links

General Publications

• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Fureder W, Ptushkin V, Rottinghaus ST, Volles L, Shafner L, Aguzzi R, Pradhan R, Schrezenmeier H, Hill A. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019 Feb 7;133(6):530-539. doi: 10.1182/blood-2018-09-876136. Epub 2018 Dec 3.
• Schwartz CE, Stark RB, Borowiec K, Nolte S, Myren KJ. Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria. Orphanet J Rare Dis. 2021 Sep 15;16(1):389. doi: 10.1186/s13023-021-02016-8.
• Schrezenmeier H, Kulasekararaj A, Mitchell L, Sicre de Fontbrune F, Devos T, Okamoto S, Wells R, Rottinghaus ST, Liu P, Ortiz S, Lee JW, Socie G. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naive to complement inhibitor therapy: open-label extension of a randomized study. Ther Adv Hematol. 2020 Oct 24;11:2040620720966137. doi: 10.1177/2040620720966137. eCollection 2020.
• Ishiyama K, Nakao S, Usuki K, Yonemura Y, Ikezoe T, Uchiyama M, Mori Y, Fukuda T, Okada M, Fujiwara SI, Noji H, Rottinghaus S, Aguzzi R, Yokosawa J, Nishimura JI, Kanakura Y, Okamoto S. Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients. Int J Hematol. 2020 Oct;112(4):466-476. doi: 10.1007/s12185-020-02934-6. Epub 2020 Aug 31.
• Brodsky RA, Peffault de Latour R, Rottinghaus ST, Roth A, Risitano AM, Weitz IC, Hillmen P, Maciejewski JP, Szer J, Lee JW, Kulasekararaj AG, Volles L, Damokosh AI, Ortiz S, Shafner L, Liu P, Hill A, Schrezenmeier H. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2021 Jan 1;106(1):230-237. doi: 10.3324/haematol.2019.236877.

Study record dates

Study Major Dates

• Study Start (Actual): December 20, 2016
• Primary Completion (Actual): January 25, 2018
• Study Completion (Actual): February 28, 2023

Study Registration Dates

• First Submitted: October 25, 2016
• First Submitted That Met QC Criteria: October 25, 2016
• First Posted (Estimate): October 27, 2016

Study Record Updates

• Last Update Posted (Estimate): May 5, 2023
• Last Update Submitted That Met QC Criteria: April 13, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urologic Diseases; Urological Manifestations; Bone Marrow Diseases; Hematologic Diseases; Urination Disorders; Anemia; Proteinuria; Anemia, Hemolytic; Myelodysplastic Syndromes; Hemoglobinuria; Hemoglobinuria, Paroxysmal; Physiological Effects of Drugs; Immunosuppressive Agents; Immunologic Factors; Complement Inactivating Agents; Eculizumab; Ravulizumab
• Other Study ID Numbers: ALXN1210-PNH-301; 2016-002025-11 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No